Text Size

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment.

Geerling, G.; Hamada, S.; Trocmé, S.; Ræder, S.; Chen, X.; Fassari, C.; Lanzl, I.


  • 2022
  • Ophthalmology and therapy
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany; Queen Victoria Hospital, East Grinstead, UK; Aleris Specialistvård Sabbatsberg, Europakliniken Department of Ophthalmology, Sabbatsbergs Hospital, Stockholm, Sweden; The Norwegian Dry Eye Clinic, Oslo, Norway; Santen SA, Geneva, Switzerland; Chiemsee Augentagesklinik, Prien, Germany

Related Publications

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.


Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022